Bausch + Lomb, a leading global eye health company, announced a voluntary recall of its Envista Aspire, Envista Envy and certain Envistar intraocular lens injector systems, according to the Food ...

Gland Pharma Limited, a generic injectable & ophthalmic focused pharmaceutical company, has received approval from the USFDA ...

EPS, expectations were $0.03. Operator: Good morning, and welcome to Bausch + Lomb’s First Quarter 2025 Earnings Call. All participants will be in listen-only mode. [Operator Instructions] Please note ...

A blank-check company led by Anthony Pompliano, a cryptocurrency influencer, podcaster and investor, has filed for an initial ...

Bausch & Lomb Corp (BLCO) reports steady revenue growth and strategic resilience despite facing headwinds from recalls and tariffs.

Consolidated Revenues of $2.26 billion, up 5% on a Reported basis and 6% on an Organic (non-GAAP) 1 basis over the prior year periodGAAP Net Loss Attributable to Bausch Health Companies of $58 million ...

Bausch & Lomb is one of the largest vision care companies in the US. Bausch spun off from its former parent company, Bausch Health, in 2022 and it now operates in three segments: vision care, surgical ...

Consolidated Revenues of $2.26 billion, up 5% on a Reported basis and 6% on an Organic (non-GAAP) 1 basis over the prior year periodGAAP Net Loss Attributable to Bausch Health Companies of ...

U.S. stock futures point to a lower open after rising Tuesday on hopes trade deals are getting done and Trump's tariff plan ...

Vision Care revenue increased by 5%, driven by Daily SiHy lenses (up 42%) and Blink products (up 85%). The Surgical segment grew by 11%, led by premium IOLs (up 77%), while Pharmaceuticals posted 1% ...

Bausch + Lomb Corporation ( NYSE: BLCO) Q1 2025 Earnings Conference Call April 30, 2025 8:00 AM ET George Gadkowski - Vice President, Investor Relations & Business Insights Brent Saunders - Chairman & ...

Bausch + Lomb updated its full-year 2025 guidance to reflect the estimated one-time impact of a voluntary recall of certain intraocular lenses. It now expects revenue of $5.0-$5.1 billion, up from its ...